Dimeric BPD Nanoparticles for Selective Ovarian Cancer PDT
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current photosensitizers like benzoporphyrin derivative (BPD) face challenges due to poor water solubility and limited tumor selectivity, leading to off-target effects and reduced therapeutic efficacy in photodynamic therapy for ovarian cancer.
Innovation Solution
A dimeric benzoporphyrin derivative (dBPD) is synthesized using a cystamine linker and encapsulated within PEGylated lipid nanoparticles, functionalized with folic acid for targeted delivery to ovarian cancer cells, leveraging glutathione-responsive release and folate receptor-mediated uptake.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If monomeric BPD is used for photodynamic therapy, then the treatment can be administered, but the drug loading efficiency is low and colloidal stability is poor
Solution Approach 1:
Two monomeric BPD molecules are merged through disulfide bond formation to create a dimeric structure. This merging increases the hydrophobic character and molecular weight of the photosensitizer, enabling higher drug loading efficiency (up to 60% w/w) and improved colloidal stability of the nanoparticle formulation
Solution Approach 2:
The patent creates a composite nanoformulation consisting of dimeric BPD encapsulated within PEGylated lipid nanoparticles. This composite structure combines the phototherapeutic properties of BPD with the stabilizing and targeting properties of the nanoparticle carrier system, achieving both high drug loading and colloidal stability
2Reliability
If conventional photosensitizers are used, then photodynamic therapy can be performed, but tumor selectivity is limited leading to off-target effects
Solution Approach 1:
The nanoparticle surface is functionalized with folic acid ligands that provide localized targeting capability. This creates a non-uniform distribution of functional groups on the nanoparticle surface, with folic acid molecules positioned to specifically bind to folate receptors on ovarian cancer cells, thereby improving tumor selectivity and reducing off-target effects
Solution Approach 2:
Folic acid acts as an intermediary molecule that mediates the interaction between the nanoparticle carrier and the target cancer cells. The folic acid-ligand binds to folate receptors on the cell surface, facilitating selective uptake of the dimeric BPD photosensitizer into ovarian cancer cells while sparing healthy tissues
3Quantity of substance
If hydrophobic photosensitizers are encapsulated in PEGylated lipid nanoparticles, then solubility is improved, but drug leakage occurs prematurely
Solution Approach 1:
The dimeric BPD structure merges two hydrophobic photosensitizer units, increasing overall hydrophobicity and enhancing interaction with the lipid bilayer of the nanoparticle. This stronger interaction reduces premature leakage while maintaining water solubility through the PEGylated lipid exterior
Solution Approach 2:
The patent changes the physical-chemical parameters of the photosensitizer by converting monomeric BPD to dimeric BPD through disulfide bond formation. This parameter change (increased molecular weight, increased hydrophobicity) improves encapsulation stability and reduces drug leakage while maintaining solubility through the nanoparticle carrier system
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances drug loading efficiency, stability, and selectivity, resulting in improved photodynamic therapy outcomes with reduced side effects on healthy tissues by selectively targeting and killing cancer cells.
Implementation Method 1
Conjugating two hydrophobic drug molecules can significantly increase their overall hydrophobicity and size compared to their monomeric forms, facilitating better encapsulation within nanoparticles and enhancing their self-assembly effect
Implementation Method 2
Photodynamic therapy (PDT) is a minimally invasive treatment in which administration of a light-activated drug (photosensitizers) is followed by irradiation at a specific wavelength leading to the production of cytotoxic reactive oxygen species
Implementation Method 3
Intriguingly, dBPD contains a disulfide linkage that can be triggered to release BPD in the presence of glutathione (GSH), a tripeptide present in high concentrations in intracellular environments
Data Source
AI summary
Photodynamic therapy (PDT) is a minimally invasive treatment that involves the administration of a light-activatable drug followed by light activation of the lesion to produce reactive oxygen species that kill cancer cells. VISUDYNE®, a liposomal formulation of benzoporphyrin derivative (BPD) photosensitizer, is clinically approved for PDT of ocular diseases and is now being tested for PDT and imaging of pancreatic, brain, and other cancers. While VISUDYNE® improves the pharmacokinetics of BPD, it lacks treatment selectivity. This present disclosure is directed to dBPD, dBPD nanoparticles, and preparation and use thereof that provide cancer treatment selectivity for cancers characterized by overexpression of folate receptor (FR).